Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTMX CytomX Therapeutics	$2.38	$2.38	$0.40 ▼ $3.10	$192.28M	2.05	2.22 million shs	673,020 shs
DRUG Bright Minds Biosciences	$26.16 +0.7%	$27.93	$0.94 ▼ $79.02	$184.27M	-6.01	827,291 shs	25,311 shs
IPSC Century Therapeutics	$0.58 +0.1%	$0.57	$0.34 ▼ $2.55	$50.04M	1.78	580,755 shs	639,676 shs
KOD Kodiak Sciences	$5.52 +6.4%	$3.93	$1.92 ▼ $11.60	$291.26M	2.28	351,388 shs	513,256 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTMX CytomX Therapeutics	0.00%	-1.65%	+12.80%	+262.80%	+65.28%
DRUG Bright Minds Biosciences	0.00%	+5.44%	-7.20%	-20.99%	+2,116.95%
IPSC Century Therapeutics	0.00%	-3.25%	-0.95%	+6.82%	-80.64%
KOD Kodiak Sciences	0.00%	+21.85%	+56.37%	+94.09%	+83.39%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CTMX CytomX Therapeutics	3.7712 of 5 stars	3.5	1.0	4.7	0.0	1.7	1.3
DRUG Bright Minds Biosciences	1.6667 of 5 stars	3.6	2.0	0.0	0.0	2.5	0.0
IPSC Century Therapeutics	3.3272 of 5 stars	3.5	5.0	0.0	2.5	1.7	0.6
KOD Kodiak Sciences	3.7244 of 5 stars	3.0	2.0	4.6	1.1	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CTMX CytomX Therapeutics	3.00	Buy	$5.33	124.09% Upside
DRUG Bright Minds Biosciences	3.13	Buy	$83.25	218.23% Upside
IPSC Century Therapeutics	3.00	Buy	$4.20	623.14% Upside
KOD Kodiak Sciences	2.00	Hold	$9.00	63.04% Upside

Current Analyst Ratings Breakdown

Latest IPSC, DRUG, CTMX, and KOD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/2/2025	DRUG Bright Minds Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight
5/21/2025	DRUG Bright Minds Biosciences	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
5/16/2025	IPSC Century Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$7.00 ➝ $6.00
5/15/2025	CTMX CytomX Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$2.50 ➝ $5.00
5/15/2025	CTMX CytomX Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$5.00 ➝ $5.00
5/13/2025	DRUG Bright Minds Biosciences	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
5/13/2025	DRUG Bright Minds Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/13/2025	DRUG Bright Minds Biosciences	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
5/12/2025	CTMX CytomX Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$5.00 ➝ $6.00
5/7/2025	DRUG Bright Minds Biosciences	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$80.00

(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CTMX CytomX Therapeutics	$138.10M	1.39	$0.36 per share	6.59	($0.01) per share	-238.00
DRUG Bright Minds Biosciences	N/A	N/A	N/A	N/A	$0.92 per share	N/A
IPSC Century Therapeutics	$6.59M	7.59	N/A	N/A	$1.90 per share	0.31
KOD Kodiak Sciences	N/A	N/A	N/A	N/A	$2.86 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CTMX CytomX Therapeutics	$31.87M	$0.48	4.96	N/A	N/A	28.22%	-553.71%	32.21%	8/14/2025 (Estimated)
DRUG Bright Minds Biosciences	-$2.06M	-$0.36	N/A	N/A	N/A	N/A	-14.56%	-14.29%	8/13/2025 (Estimated)
IPSC Century Therapeutics	-$126.57M	-$0.29	N/A	N/A	N/A	-19.10%	-10.71%	-5.96%	8/14/2025 (Estimated)
KOD Kodiak Sciences	-$176.21M	-$3.63	N/A	N/A	N/A	N/A	-115.71%	-54.17%	8/13/2025 (Estimated)

Latest IPSC, DRUG, CTMX, and KOD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	CTMX CytomX Therapeutics	-$0.05	N/A	N/A	N/A	N/A	N/A
8/14/2025	Q2 2025	IPSC Century Therapeutics	-$0.38	N/A	N/A	N/A	N/A	N/A
8/13/2025	N/A	DRUG Bright Minds Biosciences	-$0.59	N/A	N/A	N/A	N/A	N/A
8/13/2025	Q2 2025	KOD Kodiak Sciences	-$1.01	N/A	N/A	N/A	N/A	N/A
5/15/2025	Q2 2025	DRUG Bright Minds Biosciences	-$0.39	-$0.29	+$0.10	-$0.29	N/A	N/A
5/15/2025	Q1 2025	IPSC Century Therapeutics	-$0.31	$0.89	+$1.20	$0.89	$45.52 million	$109.16 million
5/14/2025	Q1 2025	KOD Kodiak Sciences	-$0.89	-$1.09	-$0.20	-$1.09	N/A	N/A
5/12/2025	Q1 2025	CTMX CytomX Therapeutics	$0.18	$0.27	+$0.09	$0.27	$35.42 million	$50.92 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CTMX CytomX Therapeutics	N/A	N/A	N/A	N/A	N/A
DRUG Bright Minds Biosciences	N/A	N/A	N/A	N/A	N/A
IPSC Century Therapeutics	N/A	N/A	N/A	N/A	N/A
KOD Kodiak Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CTMX CytomX Therapeutics	N/A	1.73	1.73
DRUG Bright Minds Biosciences	N/A	126.01	126.01
IPSC Century Therapeutics	N/A	11.70	11.70
KOD Kodiak Sciences	N/A	4.62	4.62

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CTMX CytomX Therapeutics	67.77%
DRUG Bright Minds Biosciences	40.52%
IPSC Century Therapeutics	50.20%
KOD Kodiak Sciences	89.06%

Insider Ownership

Company	Insider Ownership
CTMX CytomX Therapeutics	6.60%
DRUG Bright Minds Biosciences	42.66%
IPSC Century Therapeutics	5.00%
KOD Kodiak Sciences	45.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CTMX CytomX Therapeutics	170	80.62 million	75.30 million	Optionable
DRUG Bright Minds Biosciences	N/A	7.04 million	4.04 million	Not Optionable
IPSC Century Therapeutics	170	86.16 million	81.85 million	Optionable
KOD Kodiak Sciences	90	52.76 million	28.55 million	Optionable

IPSC, DRUG, CTMX, and KOD Headlines

Recent News About These Companies

Tsunami alerts for Alaska canceled after 7.3-magnitude earthquake off Aleutians

July 18 at 9:29 AM | msn.com

Part 1: Johnson recounts PTSD treatment after May breakdown

July 17 at 4:08 AM | kodiakdailymirror.comK

Enduring the heat of California

July 15, 2025 | kodiakdailymirror.comK

Penny Stocks To Watch In July 2025

July 11, 2025 | finance.yahoo.com

NASDAQ:KOD Financials | Kodiak Sciences Inc - Investing.com

July 10, 2025 | investing.com

Kodiak Sciences to Host Investor R&D Day on July 16, 2025

July 10, 2025 | prnewswire.com

Peapod Lane Capital LLC Trims Position in Kodiak Sciences Inc. (NASDAQ:KOD)

July 10, 2025 | marketbeat.com

Kodiak Sciences (NASDAQ:KOD) Stock Price Up 5.1% - Time to Buy?

July 9, 2025 | marketbeat.com

Kodiak Sciences Inc. Advanced Charts | KOD | Barron's

July 9, 2025 | barrons.com

Kodiak Sciences to Present KSI-101 Highlights at 2025 Congress of the International Ocular Inflammation Society - Morningstar

June 27, 2025 | morningstar.comM

Kodiak Sciences to present KSI-101 highlights at the 2025 Congress of the International Ocular Inflammation Society (IOIS)

June 27, 2025 | ophthalmologytimes.comO

Kodiak Sciences to Present KSI-101 Highlights at 2025 Congress of the International Ocular Inflammation Society

June 25, 2025 | prnewswire.com

Why Is Kodiak Sciences (KOD) Up 10.5% Since Last Earnings Report?

June 13, 2025 | zacks.com

Trump’s cuts to fisheries science have industry and conservation groups sounding alarm

June 11, 2025 | kucb.orgK

Alaska Aerospace, UAF to partner on new space ventures

June 11, 2025 | kodiakdailymirror.comK

Retinal Vein Occlusion Pipeline Appears Robust With 15+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

June 5, 2025 | theglobeandmail.com

Kodiak Sciences to Present at 2025 Jefferies Global Healthcare Conference

May 29, 2025 | prnewswire.com

Kodiak Sciences’ SWOT analysis: eye disease biotech stock at crossroads

May 29, 2025 | investing.com

Kodiak Sciences Inc.: Kodiak Sciences Announces Recent Business Highlights and First Quarter 2025 Financial Results

May 15, 2025 | finanznachrichten.de

Kodiak Sciences Shares Drop After Wider-Than-Expected 1Q Loss

May 15, 2025 | marketwatch.com

Kodiak Q1 Loss Wider Than Expected, Pipeline Development in Focus

May 15, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
Why Hims & Hers Is a Buy Below $35 After Its 16% Pullback
By Gabriel Osorio-Mazilli | July 3, 2025
View Why Hims & Hers Is a Buy Below $35 After Its 16% Pullback
Nektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?
By Leo Miller | June 28, 2025
View Nektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?

IPSC, DRUG, CTMX, and KOD Company Descriptions

CytomX Therapeutics NASDAQ:CTMX

$2.38 0.00 (0.00%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$2.40 +0.02 (+0.84%)

As of 07/18/2025 07:50 PM Eastern

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Bright Minds Biosciences NASDAQ:DRUG

$26.16 +0.17 (+0.65%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$26.27 +0.11 (+0.42%)

As of 07/18/2025 07:35 PM Eastern

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.

Century Therapeutics NASDAQ:IPSC

$0.58 +0.00 (+0.10%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$0.59 +0.01 (+2.10%)

As of 07/18/2025 07:36 PM Eastern

Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

Kodiak Sciences NASDAQ:KOD

$5.52 +0.33 (+6.36%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$5.46 -0.06 (-1.18%)

As of 07/18/2025 07:40 PM Eastern

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time